Molecular dynamics simulations of the three systems (TNF-MOL000098, TNF-MOL000354, TNF-MOL000422) after 50 ns. by Lefei Yu (12274846)

Mean of the difference between the RV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

Mean of the difference between the LV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

The %change in GABA level had a trend correlation with MEP amplitude in the left sensorimotor area (R = −0.43002, R2 = 0.1849, t = 1.844717, p = 0.082575). by Hiroyuki Matsuta (13250169)

Subjects:

Mean score of school factors by SES over years. by Benti Geleta Buli (15417868)

Decreases in muscle size, muscle force, and TB mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

Decreased expression of V-ATPase upon the siRNA transfection. by Manisha Naskar (2613763)

Discrimination performance deteriorated as the safe-to-conditioned ΔF decreased. by Chi Chen (67021)

Trends ARI symptoms of Cambodia children aged between 0–59 months, CDHS 2000 to 2014. by Samnang Um (14990562)

Trends of children aged 0–59 months with ARI symptoms by survey years, CDHS 2000 to 2014. by Samnang Um (14990562)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Increased levels of PPARγ and decreased levels of adiponectin in thymus from rats administered cocaine for 7 days. by Kana Unuma (283272)

<i>clec-4(ok2050)</i> and <i>clec-4(ya1)</i> decrease <i>C</i>. <i>elegans</i> feeding leading to a reduced bacterial load. by Barbara Pees (3313560)

Distribution of mean scores of mental health problems by year of survey and SES. by Benti Geleta Buli (15417868)

Whole sample storing experiment: Mean FECs of day 0, day 1 and day 2 for hookworm, <i>A</i>. <i>lumbricoides</i> and <i>T</i>. <i>trichiura</i>. by Felix Bosch (10024550)

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…GCase activity measured by 4-MU in liver (B) measured as follows: WT 4mo 93.69±7.16, HOM 4mo 3.90±0.21, WT 8mo 112.40±6.84, HOM 8mo 1.50±0.19, WT 12 mo 96.79±7.44, HOM 12mo 3.50±0.58. …”

Means for STEM competence for pre- and post-test. by Esther Kim (2996622)

“…After the Challenge, participants increased in awareness of global issues, and engagement with others, but also showed a small but significant decrease in respect for people from other cultural backgrounds. …”

ACT and ISO decrease pathological changes in LPS-induced AKI mice. by Jing Lian (1671991)

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial by Daniëlle B. P. Eekers (5560430)